Developing the solution to treat life-threatening inflammation

Saving millions
of lives by
effectively neutralizing Extracellular Cytotoxic Histones

Matisse pharmaceuticals is developing the first life-saving treatment targeting the root cause of sepsis

Matisse Pharmaceuticals B.V. Matisse Pharmaceuticals B.V. Matisse Pharmaceuticals B.V.

About us

Matisse Pharmaceuticals BV is a biopharmaceutical clinical stage company developing a product portfolio of safe and innovative therapies. It focuses on disease indications characterized by elevated levels of extracellular cytotoxic histones, such as in sepsis and septic shock.

About Matisse
Our mission Saving millions of lives by effectively neutralizing extracellular cytotoxic histones
Our vision To become the first company worldwide to effectively combat sepsis

What is Sepsis

Sepsis is a serious medical condition characterized as systemic inflammatory response syndrome (SIRS) caused by an infection. In case of sepsis and septic shock, additional complications occur including acute organ dysfunction and persistent reduced blood pressure. Sepsis and septic shock are leading causes of death and present a major clinical problem in the management of patients in the intensive care unit (ICU).

Partnering

Partnering

Matisse Pharmaceuticals has built a network of strategic partners to achieve its goals. We aim to extend this network further, as we strongly believe that important goals can only be reached in collaboration.

Feel free to contact us any time in case you believe you can add value to Matisse in achieving its mission to save millions of lives by effectively combating cytotoxic histones. Contact us

Our partners

Amsterdam UMC
Maastricht University
Maastricht UMC+
Basic Pharma